Abstracts

HCV CURE IN HIV COINFECTION DAMPENS INFLAMMATION AND IMPROVES COGNITION

Chronic inflammation in HIV/HCV coinfection increases cognitive impairment. With new direct-acting antiviral therapies for HCV, sustained viral response (SVR) or cure is possible. Our objective was to determine if chronic inflammation and cognitive impairment in coinfection would be decreased after HCV SVR. We studied 41 participants before and after treatment for HCV alone or with…

KINETICS OF EMERGENCE OF LIVER COMPLICATIONS IN HCV-INFECTED PATIENTS AFTER SVR

Despite achieving SVR with DAA-based regimens, a few HCV-infected patients still develop liver complications. Consequently, life-long surveillance for hepatic events, including hepatocellular carcinoma (HCC), is recommended among individuals with pre-treatment cirrhosis. However, there is little available evidence on the distribution over time of these liver complications’ appearing after SVR. Thus, the aim of this study…

EFFECT OF DAA REGIMENS ON MORTALITY IN HIV/HCV-COINFECTED PATIENTS WITH CIRRHOSIS

Our objective was to assess the impact of all-oral direct antiviral agents (DAA) regimens on mortality in HIV/HCV-coinfected patients with cirrhosis. 637 HIV/HCV-coinfected patients with cirrhosis prospectively recruited in the HEPAVIR-cirrhosis cohort from 2006 were followed-up until death or December 2018. The primary end-point was death of any cause and secondary end-point was liver-related death.…

HIV COINFECTION AND RISK OF MORBIDITY AND MORTALITY IN HCV PATIENTS TREATED BY DAA

HIV co-infection leads to increased mortality, liver disease progression and extra-hepatic manifestations in HCV-infected patients. DAA lead to high SVR rates and decrease the risk of disease progression. We compared risks of liver-related events, liver-related mortality and non-liver-related mortality in HIV/HCV co-infected and HCV mono-infected patients treated by DAA. Four HCV mono-infected participants from the…

REAL-WORLD EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR FOR HEPATITIS C VIRUS INFECTION

Glecaprevir and pibrentasvir (GLE/PIB) are direct-acting antiviral agents (DAAs) with pan-genotypic activity and a high barrier to resistance. We evaluated the effectiveness and safety of GLE/PIB in a large prospective registry HCV-infected individuals with/without coinfection by HIV and receiving DAAs for HCV infection. RUA-VHC (Madrid Registry of Use of DAA for HCV) is a prospective…